Partnership will expand research into ‘urgently needed’ area

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	Aramyan)
(Image: Getty/ Aramyan)

Related tags: Research, Research and development, technological, compound, assays, Drug discovery

SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.

The research collaboration will leverage Schrödinger’s advanced computational platform​ and Sun Pharma Advanced Research Company’s (SPARC) understanding of neurodegeneration.

A spokesperson for Schrödinger said the collaboration aims to accelerate novel development candidates for target pathways “of emerging interest and significance in neurodegeneration.”

“SPARC has some very interesting insights that we think hold a lot of promise for drug development,”​ the spokesperson told us.

Schrödinger remains focused on drug discovery through molecular simulation and will provide all computational analyses, and lead discovery and optimization. SPARC, a clinical-stage company, will be responsible for compound synthesis and assays. The teams will use Schrödinger’s LiveDesign platform to collaborate on the process.

In a statement made by Ramy Farid, president and CEO of Schrödinger he said, “This research collaboration is particularly exciting because neurodegeneration is an area where we urgently need more options for patients through novel approaches to drug discovery and development.”

Sparc’s CEO, Anil Raghavan, stated that prior to this collaboration, it has used Schrödinger’s software for years and has “experienced directly the power of [its] physics-based approaches to computational modeling.”

SPARC is not the only company to enter into a c​ollaboration with Schrödinger recently. WuXi AppTec and Schrödinger recently launched​ a ‘virtual global collaboration.’

Additionally, Schrödinger in 2016 co-founded Nimbus Therapeutics through a drug discovery collaboration. From that collaboration, the company sold an ACC inhibitor to Gilead in a $1.2bn deal.

Takeda also signed a research collaboration​ with Schrödinger to examine multiple targets through Schrödinger’s in silico​ platform-driven drug discovery capabilities.

 

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Related suppliers

Follow us

Products

View more

Webinars